We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
Read MoreHide Full Article
Key Takeaways
Intellia posted a Q3 loss of 92 cents per share, narrower than the expected $1.02 loss.
Revenues rose 51% to $13.8M, driven by collaboration reimbursements from Regeneron.
Withdrawal of milestone guidance for nex-z after an earlier FDA hold fueled a sharp 25% stock drop.
Intellia Therapeutics (NTLA - Free Report) reported third-quarter 2025 loss of 92 cents per share (including one-time expenses of change in fair value of investments), narrower than the Zacks Consensus Estimate of a loss of $1.02. In the year-ago quarter, the company had incurred a loss of $1.34 per share.
Intellia’s total revenues currently comprise only collaboration revenues. Intellia reported revenues of $13.8 million for the third quarter of 2025, missing the Zacks Consensus Estimate of $16 million. The figure increased 51% on a year-over-year basis, driven by cost reimbursements related to NTLA’s collaboration with Regeneron Pharmaceuticals (REGN - Free Report) .
The stock has crashed around 29% in the pre-market hours today as the investors are disappointed by the mixed nature of the earnings results. The downward trend was further aggravated as an important pipeline candidate, nexiguran ziclumeran (nex-z), currently being developed for two cardiovascular indications in separate late-stage studies, faced a significant regulatory setback.
The regulatory blow has cast doubt on the outlook for lonvoguran ziclumeran (lonvo-z), Intellia’s remaining phase III asset aimed at treating hereditary angioedema (HAE). This makes NTLA’s HAE study outcome, to be reported next year, increasingly central to its near-term success.
NTLA’s Q3 Earnings in Detail
Intellia’s collaboration revenues beat our model estimate of $12.1 million.
Research and development expenses totaled $94.7 million, down 23% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and other costs, partially offset by increased spending in pipeline activities.
Year to date, NTLA shares have lost 19% against the industry’s 11.5% growth.
Image Source: Zacks Investment Research
General and administrative expenses of $30.5 million were flat on a year-over-year basis.
As of Sept. 30, 2025, Intellia had cash, cash equivalents and marketable securities worth $669.9 million compared with $630.5 million as of June 30, 2025. The company expects this cash balance to fund its ongoing operations into mid-2027 and the anticipated first commercial launch.
NTLA's Recent Pipeline Updates
Intellia has collaborated with Regeneron for the development of its investigational in vivo genome-editing candidate, nex-z, which is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Nex-z is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits.
Last month, Intellia disclosed that the FDA placed a clinical hold on its phase III MAGNITUDE and MAGNITUDE-2 studies for ATTR-CM and ATTRv-PN, respectively. The studies include more than 650 patients with ATTR-CM and 47 patients with ATTRv-PN. So far, Grade 4 liver enzyme elevations have been observed in under 1% of the MAGNITUDE study patients and none in the MAGNITUDE-2 study.
In response, NTLA has tightened post-dosing monitoring of patients and is working with investigators and regulators to understand the issue and develop additional risk-mitigation strategies. With the clinical hold in place, Intellia has suspended its milestone guidance for nex-z and will provide an update once a regulatory path forward is established.
Intellia is developing another pipeline candidate, lonvo-z, for the treatment of HAE. NTLA completed enrolling HAE patients in the pivotal phase III HAELO study evaluating lonvo-z in September 2025 and now expects to share top-line data by mid-2026. Intellia dosed the first patient in the HAELO study in January 2025.
The company remains on track to submit a potential biologics license application for NTLA-2002 in HAE in the second half of 2026.
Intellia Therapeutics, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 67.6%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
In the past 60 days, estimates for Acadia Pharmaceuticals’ earnings per share have increased from 52 cents to 53 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 78 cents to 84 cents. Year to date, shares of ACAD have surged 21.7%.
Acadia Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 24.87%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
Key Takeaways
Intellia Therapeutics (NTLA - Free Report) reported third-quarter 2025 loss of 92 cents per share (including one-time expenses of change in fair value of investments), narrower than the Zacks Consensus Estimate of a loss of $1.02. In the year-ago quarter, the company had incurred a loss of $1.34 per share.
Intellia’s total revenues currently comprise only collaboration revenues. Intellia reported revenues of $13.8 million for the third quarter of 2025, missing the Zacks Consensus Estimate of $16 million. The figure increased 51% on a year-over-year basis, driven by cost reimbursements related to NTLA’s collaboration with Regeneron Pharmaceuticals (REGN - Free Report) .
The stock has crashed around 29% in the pre-market hours today as the investors are disappointed by the mixed nature of the earnings results. The downward trend was further aggravated as an important pipeline candidate, nexiguran ziclumeran (nex-z), currently being developed for two cardiovascular indications in separate late-stage studies, faced a significant regulatory setback.
The regulatory blow has cast doubt on the outlook for lonvoguran ziclumeran (lonvo-z), Intellia’s remaining phase III asset aimed at treating hereditary angioedema (HAE). This makes NTLA’s HAE study outcome, to be reported next year, increasingly central to its near-term success.
NTLA’s Q3 Earnings in Detail
Intellia’s collaboration revenues beat our model estimate of $12.1 million.
Research and development expenses totaled $94.7 million, down 23% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and other costs, partially offset by increased spending in pipeline activities.
Year to date, NTLA shares have lost 19% against the industry’s 11.5% growth.
Image Source: Zacks Investment Research
General and administrative expenses of $30.5 million were flat on a year-over-year basis.
As of Sept. 30, 2025, Intellia had cash, cash equivalents and marketable securities worth $669.9 million compared with $630.5 million as of June 30, 2025. The company expects this cash balance to fund its ongoing operations into mid-2027 and the anticipated first commercial launch.
NTLA's Recent Pipeline Updates
Intellia has collaborated with Regeneron for the development of its investigational in vivo genome-editing candidate, nex-z, which is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Nex-z is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits.
Last month, Intellia disclosed that the FDA placed a clinical hold on its phase III MAGNITUDE and MAGNITUDE-2 studies for ATTR-CM and ATTRv-PN, respectively. The studies include more than 650 patients with ATTR-CM and 47 patients with ATTRv-PN. So far, Grade 4 liver enzyme elevations have been observed in under 1% of the MAGNITUDE study patients and none in the MAGNITUDE-2 study.
In response, NTLA has tightened post-dosing monitoring of patients and is working with investigators and regulators to understand the issue and develop additional risk-mitigation strategies. With the clinical hold in place, Intellia has suspended its milestone guidance for nex-z and will provide an update once a regulatory path forward is established.
Intellia is developing another pipeline candidate, lonvo-z, for the treatment of HAE. NTLA completed enrolling HAE patients in the pivotal phase III HAELO study evaluating lonvo-z in September 2025 and now expects to share top-line data by mid-2026. Intellia dosed the first patient in the HAELO study in January 2025.
The company remains on track to submit a potential biologics license application for NTLA-2002 in HAE in the second half of 2026.
Intellia Therapeutics, Inc. Price, Consensus and EPS Surprise
Intellia Therapeutics, Inc. price-consensus-eps-surprise-chart | Intellia Therapeutics, Inc. Quote
NTLA’s Zacks Rank & Stocks to Consider
Intellia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) and Acadia Pharmaceuticals (ACAD - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 67.6%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
In the past 60 days, estimates for Acadia Pharmaceuticals’ earnings per share have increased from 52 cents to 53 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 78 cents to 84 cents. Year to date, shares of ACAD have surged 21.7%.
Acadia Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 24.87%.